Altamira Therapeutics Ltd.AA

Altamira Therapeutics Ltd.

0.0947USDD
−0.0011−1.19%
At close at Jun 9, 19:35 GMT
USD
No trades
See on Supercharts
Next report date
September 3
Report period
H1 2025
EPS estimate
−0.66 USD
Revenue estimate
0.00 USD
Market capitalization
‪541.25 K‬USD
−2.9893USD
‪−8.46 M‬USD
0.00USD
‪4.40 M‬
Beta (1Y)
1.96
Employees (FY)
13
Change (1Y)
+1 +8.33%
Revenue / Employee (1Y)
0.00USD
Net income / Employee (1Y)
‪−650.60 K‬USD

About Altamira Therapeutics Ltd.


CEO
Thomas Meyer
Headquarters
Hamilton
Founded
2003
FIGI
BBG006R5ZMC5
Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.
Performance
‪−18,550.00%‬
‪−14,050.00%‬
‪−9,550.00%‬
‪−5,050.00%‬
‪−550.00%‬
H2 '21
H1 '22
H1 '23
H1 '24
H2 '24
‪‪−12.00 M‬‬
‪‪−8.00 M‬‬
‪‪−4.00 M‬‬
‪0.00‬
‪‪4.00 M‬‬
Revenue
Net income
Net margin %
Revenue to profit conversion
Revenue
COGS
Gross profit
Op expenses
Op income
Non-Op income/ expenses
Taxes & Other
Net income
‪‪−4.40 M‬‬
‪‪−3.30 M‬‬
‪‪−2.20 M‬‬
‪‪−1.10 M‬‬
‪0.00‬
Revenue
COGS
Gross profit
Expenses & adjustments
Net income
‪‪−4.40 M‬‬
‪‪−3.30 M‬‬
‪‪−2.20 M‬‬
‪‪−1.10 M‬‬
‪0.00‬
Debt level and coverage
H2 '21
H1 '22
H1 '23
H1 '24
H2 '24
‪‪−10.00 M‬‬
‪‪−5.00 M‬‬
‪0.00‬
‪‪5.00 M‬‬
‪‪10.00 M‬‬
Debt
Free cash flow
Cash & equivalents
Earnings
Next:Sep 3, 2025
H1 '20
H2 '20
H1 '24
H2 '24
H1 '25
‪−600.00‬
‪−450.00‬
‪−300.00‬
‪−150.00‬
‪0.00‬
Actual
Estimate

No news here

Looks like there's nothing to report right now

Summarizing what the indicators are suggesting.
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Oscillators
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Summary
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Moving Averages
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of CYTOF is 0.0947 USD — it has decreased by −1.19% in the past 24 hours. Watch Altamira Therapeutics Ltd. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange Altamira Therapeutics Ltd. stocks are traded under the ticker CYTOF.
CYTOF stock has fallen by −5.30% compared to the previous week, the month change is a 35.29% rise, over the last year Altamira Therapeutics Ltd. has showed a −93.51% decrease.
CYTOF reached its all-time high on Jan 6, 2016 with the price of 1,273,600.0000 USD, and its all-time low was 0.0501 USD and was reached on Apr 7, 2025. View more price dynamics on CYTOF chart.
See other stocks reaching their highest and lowest prices.
CYTOF stock is 10.56% volatile and has beta coefficient of 1.96. Track Altamira Therapeutics Ltd. stock price on the chart and check out the list of the most volatile stocks — is Altamira Therapeutics Ltd. there?
Today Altamira Therapeutics Ltd. has the market capitalization of ‪541.26 K‬, it has decreased by −10.50% over the last week.
Yes, you can track Altamira Therapeutics Ltd. financials in yearly and quarterly reports right on TradingView.
Altamira Therapeutics Ltd. is going to release the next earnings report on Sep 3, 2025. Keep track of upcoming events with our Earnings Calendar.
CYTOF net income for the last half-year is ‪−4.12 M‬ USD, while the previous report showed ‪−4.34 M‬ USD of net income which accounts for 5.11% change. Track more Altamira Therapeutics Ltd. financial stats to get the full picture.
No, CYTOF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jun 12, 2025, the company has 13 employees. See our rating of the largest employees — is Altamira Therapeutics Ltd. on this list?
Like other stocks, CYTOF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Altamira Therapeutics Ltd. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Altamira Therapeutics Ltd. technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Altamira Therapeutics Ltd. stock shows the sell signal. See more of Altamira Therapeutics Ltd. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.